Related references
Note: Only part of the references are listed.Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial
Sabrina H. Tsang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing
Sarah Wagner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes
Sarah Wagner et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial
Feng-Cai Zhu et al.
CANCER MEDICINE (2019)
Vaccination protects against invasive HPV-associated cancers
Tapio Luostarinen et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country
Emily A. Burger et al.
VACCINE (2018)
Explanations for the high potency of HPV prophylactic vaccines
John Schiller et al.
VACCINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Susanne K. Kjaer et al.
CLINICAL INFECTIOUS DISEASES (2018)
Worldwide burden of cancer attributable to HPV by site, country and HPV type
Catherine de Martel et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial
Warner K. Huh et al.
LANCET (2017)
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials
Matti Lehtinen et al.
BMJ OPEN (2017)
Finite sample pointwise confidence intervals for a survival distribution with right-censored data
Michael P. Fay et al.
STATISTICS IN MEDICINE (2016)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica
Paula Gonzalez et al.
VACCINE (2015)
Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing
Carolina Porras et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
Allan Hildesheim et al.
VACCINE (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica
Rolando Herrero et al.
VACCINE (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR
Leen-Jan van Doorn et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
The 2001 Bethesda System - Terminology for reporting results of cervical cytology
D Solomon et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Share Paper
